In addition to CC-11050, the beneficial effect of another phosphodiesterase 4B inhibitor (BI 1015550) has been tested in patients with idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis (72–75). Here, PDE4B is linked to pulmonary fibrosis.